Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
Paolo Tarantino(Harvard University), Sarah Sammons(Dana-Farber Cancer Institute), Ian E. Krop(Yale Cancer Center), Nancy U. Lin(Dana-Farber Cancer Institute), Sara M. Tolaney(Harvard University), Eric P. Winer(University of Vermont), Cary P. Gross(Yale Cancer Center), Maryam B. Lustberg(Yale Cancer Center), David Lee(AbbVie (United States)), Julia Foldi(University of Pittsburgh), Pamela R. Soulos(Yale University), Thomas Grinda(Institut Gustave Roussy)
Cited by 19
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
|Cancer Discovery|2019|1.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k